u/maren_sorensen

the second-level appeal is where things actually turn

employer plans and individual plans are different fights

prior authorisation criteria change every plan year

write the reconstitution date on the vial

That advice is jurisdiction-specific and this board spans several. Say where you are.

regional stock removes most of this problem entirely

Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.

Not convinced. That is a formulary exclusion rather than a prior authorisation denial, and the route to challenge it is different.

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

Holding off on any opinion until phase 3 reports.

This is the fact the whole board hangs on. Small molecule, not peptide.

the pharmacy and the prescriber are two separate questions

Push back: the ranking is not hiding anything. The formula is published and you can reproduce the ordering.

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

Disagree with the panic framing.

Adding the practical version: ask which lines are held regionally before you order in July.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

Kept a log with every date, name of department and reference number. When they claimed no record of a call, I had the reference.

if a clinic will not name the facility, that is your answer

Yes — a logger in the box turns a fortnight of speculation into a chart.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

ATTAIN and ACHIEVE are the programmes to keep straight

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Careful. "The cold chain failed" is a strong claim and the evidence you have is a warm box.

This. Step therapy is a paperwork requirement and it is beaten with documentation, not persuasion.

nobody here is paid, including the moderators

keep every date, every reference number, every name of a department

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

step therapy is a documentation problem, not an argument

Did they name the facility?

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

Step therapy requires documented trial of preferred alternatives. It is not an argument to be won on merits; it is a record to be produced, and the record is what the appeal must contain.

This. The absence of food and water timing restrictions is the practical difference people will actually notice.

Daily dosing, so what does the exposure profile look like across the day?

a non-peptide agonist does not degrade the way a peptide does

Moved everything off the fridge door after reading a thread here and my temperature log immediately got boring.

Ordered from the warehouse in France instead of origin and the transit went from a fortnight to 9 days.

Disagreeing with this line only: freezing a reconstituted vial is not a safe default.

Small fix — archiving happens at a year, not at six months. It is in the published policy.

Right, and keeping every date and reference number turns a frustrating process into an auditable one.

Once in solution, the relevant risks are hydrolysis, aggregation and, for some sequences, oxidation. Refrigeration slows all three; freezing a solution introduces a separate risk at the ice interface.